Long-term pretreatment with proton pump inhibitor and<i>Helicobacter pylori</i>eradication rates

Yoon, Seung Bae; Park, Jae Myung; Lee, Jong-Yul; Baeg, Myong Ki; Lim, Chul-Hyun; Cho, Yu Kyung; Lee, In Seok; Kim, Sang Woo

doi:10.3748/wjg.v20.i4.1061

Cited by 17 publications

(25 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several previous studies showed controversial effect of PPI pretreatment on the H. pylori eradication which is beneficial or harmful, 36,37 but recent data showed no significant effect of PPI pretreatment on eradication rate, so this subject still needs to be verified. 38 We consider relatively small number of diabetic patients and short course of eradication regimen which was standard regimen at the time of study design but are not popular nowadays are the main limitations in this study. But this study clearly shows and compares the eradication rate of diabetic patients and non-diabetic subjects.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study

et al. 2019

View full text Add to dashboard Cite

Objective: To compare Helicobacter pylori ( H. pylori ) eradication rate of type 2 diabetic patients with non-diabetic subjects. Methods: In this multicenter prospective observational study, H. pylori -infected subjects were enrolled from three university-affiliated hospitals. Eradication regimen was triple therapy with standard dose of proton pump inhibitors (b.i.d), amoxicillin (1.0 g b.i.d), and clarithromycin (500 mg b.i.d) for 7 days. Urea breath test was performed 4 weeks after treatment. Various clinical and laboratory data were collected for identification of factors associated with successful eradication. Results: Totally, 144 subjects were enrolled and 119 (85 non-diabetic and 34 diabetic patients) were finally analyzed. Eradication rate was 75.6% and there was no difference between diabetic patients and non-diabetic subjects (73.5% vs 76.5%, p value: 0.814). Adverse drug reactions were reported in 44.5% of patients. In multivariate analysis for predicting H. pylori eradication in diabetic patients, HbA1c (⩾7.5%) was a significant factor affecting eradication rate (adjusted odds ratio: 0.100, 95% confidence interval: 0.011–0.909, p value: 0.041). Conclusion: Diabetes itself is not a major factor affecting H. pylori eradication. However, poor glucose control may harmfully affect H. pylori eradication.

show abstract

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Helical type of H. pylori may be transformed into coccoid type. Coccoid type is less vulnerable with low antigenicity and less vulnerable in gastric lining with low production of cytotoxic protein products (CagA), arginase RocF, tumor necrosis factor- α (TNF- α ), and others [171]. This makes H. pylori escape from immune response more easily [169, 170, 172, 173].…”

Section: Helicobacter Pylori Infection In Epithelial Cellsmentioning

confidence: 99%

Status of Epstein-Barr Virus Coinfection withHelicobacter pyloriin Gastric Cancer

Singh

Jha

2017

Journal of Oncology

View full text Add to dashboard Cite

Epstein-Barr virus is a ubiquitous human herpesvirus whose primary infection causes mononucleosis, Burkett's lymphoma, nasopharyngeal carcinoma, autoimmune diseases, and gastric cancer (GC). The persistent infection causes malignancies in lymph and epithelial cells. Helicobacter pylori causes gastritis in human with chronic inflammation. This chronic inflammation is thought to be the cause of genomic instability. About 45%-word population have a probability of having both pathogens, namely, H. pylori and EBV. Approximately 180 per hundred thousand population is developing GC along with many gastric abnormalities. This makes GC the third leading cause of cancer-related death worldwide. Although lots of research are carried out individually for EBV and H. pylori, still there are very few reports available on coinfection of both pathogens. Recent studies suggested that EBV and H. pylori coinfection increases the occurrence of GC as well as the early age of GC detection comparing to individual infection. The aim of this review is to present status on coinfection of both pathogens and their association with GC.

show abstract

“…34,35 However, all the studies are based on was used with amoxicillin and clarithromycin. [41][42][43][44][45][46] Through statistical analysis, a median 24-h intragastric pH of 5.7…”

Section: Discussionmentioning

confidence: 99%

The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy

et al. 2020

Helicobacter

View full text Add to dashboard Cite

Background This study aimed to investigate whether an increased proton pump inhibitor (PPI) dose enhanced the efficacy of Helicobacter pylori (H. pylori) eradication and determine the appropriate cutoff intragastric pH value that could predict H. pylori eradication with bismuth‐based quadruple therapy. Materials and Methods A total of 207 H. pylori infected, treatment naive patients were enrolled in this prospective, open‐label, randomized controlled trial. Patients were randomly allocated into Eso40‐group (esomeprazole 40 mg bid) and Eso20‐group (esomeprazole 20 mg bid), and their CYP2C19 genotyping status was assessed. The 24‐h intragastric pH monitoring on day 7 was performed, and percentage of time gastric pH ≥ 3, ≥4, ≥5, and ≥6 (pH holding time ratios; HTRs) were measured. H. pylori eradication was evaluated using 13C‐urea breath test. Results No significant difference in the eradication rates was observed between two groups. The median 24‐h intragastric pH value was not significant different between two groups but the Eso40 Group had a significant higher pH4 HTRs (91.11% [95%CI: 87.50%–95.83%] vs. 95.83% [95.83%–100%]; p = .002). Additionally, the median 24‐h intragastric pH value showed significantly difference between two groups in EM genotype (Eso20 Group 6.00 [95%CI; 5.75–6.15] vs. Eso40 Group 6.30 [6.05–6.30]; p = .019). Similar results were observed in pH4 HTRs. There were significant differences in intragastric pH value (6.10 [95%CI: 4.40–7.00] vs. 5.65 [4.85–5.95], p = .038) and in pH4 HTRs (96% [95%CI: 92.00%–96.00%] vs. 87.5% [67.00%–100.0%], p = .019) between eradication‐successful and eradication‐failed patients. Statistical analysis suggested that the median intragastric pH = 5.7 could identify the success of H. pylori eradication. Conclusions Bismuth‐based quadruple therapy resulted in high H. pylori eradication rates either in PPI standard or double doses. Double dose of esomeprazole is associated with better intragastric acid suppression. A median 24‐h intragastric pH of 5.7 could be appropriate cutoff value for predicting the successful H. pylori eradication.

show abstract

Long-term pretreatment with proton pump inhibitor andHelicobacter pylorieradication rates

Abstract: PPI pretreatment did not affect H. pylori eradication rate, regardless of the medication period.

Cited by 17 publications

References 0 publications

Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study

Helicobacter pylori eradication in patients with type 2 diabetes mellitus: Multicenter prospective observational study

Status of Epstein-Barr Virus Coinfection withHelicobacter pyloriin Gastric Cancer

The appropriate cutoff gastric pH value for Helicobacter pylori eradication with bismuth‐based quadruple therapy

Contact Info

Product

Resources

About